APA (7th ed.) Citation

Carsten Flohr, Michael J. Cork, Michael R. Ardern-Jones, Lawrence F. Eichenfield, Sébastien Barbarot, Claire Feeney, . . . John Nesnas. (2023). Efficacy and safety of abrocitinib monotherapy in adolescents and adults: A post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Carsten Flohr, Michael J. Cork, Michael R. Ardern-Jones, Lawrence F. Eichenfield, Sébastien Barbarot, Claire Feeney, Ricardo Rojo, Irina Lazariciu, and John Nesnas. Efficacy and Safety of Abrocitinib Monotherapy in Adolescents and Adults: A Post Hoc Analysis of the Phase 3 JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN Clinical Trial. Taylor & Francis Group, 2023.

MLA (9th ed.) Citation

Carsten Flohr, et al. Efficacy and Safety of Abrocitinib Monotherapy in Adolescents and Adults: A Post Hoc Analysis of the Phase 3 JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN Clinical Trial. Taylor & Francis Group, 2023.